Yemaachi and Institut Pasteur Tunis Forge Oncogenetics Partnership to Sequence and Characterise Inflammatory Breast Cancer in Patients of African Descent
Partnership is emblematic of a global effort to characterise cancer development and progression in individuals of African descent, who have traditionally been excluded from genomic oncology studies and clinical trials 22nd October 2024, Tunis, Tunisia — Precision oncology company Yemaachi Biotech and Institut Pasteur Tunis today announced a research partnership investigating genomics in inflammatory breast […]
Liquid Biopsy – The necessary first step towards democratising precision oncology?
While IHC and imaging are useful for diagnosing and staging cancers, they are limited in their ability to inform clinical decision-making regarding the use of increasingly available targeted therapies that are revolutionising cancer care in developed countries. For this, more advanced molecular tests are required, and next generation sequencing-based liquid biopsy tests are at the cutting edge.
African biotech holds the key to transforming not just the health of African people, but our economies as well
Why has over a decade of political rhetoric and unprecedented donor support for scientific capacity building not translated into more tangible scientific output?
A closer look reveals a glaring gap in the current structure of the scientific ecosystem in Africa – the almost complete absence of the private sector.